184 related articles for article (PubMed ID: 38188537)
1. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.
Kingston P; Blauvelt A; Strober B; Armstrong AW
J Psoriasis Psoriatic Arthritis; 2023 Oct; 8(4):156-165. PubMed ID: 38188537
[TBL] [Abstract][Full Text] [Related]
2. Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.
Truong TM; Pathak GN; Singal A; Taranto V; Rao BK
Ann Pharmacother; 2024 Apr; 58(4):416-427. PubMed ID: 37341177
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Qiu J; Liu J; Liu W; Lin F; Shi N
Front Med (Lausanne); 2023; 10():1264667. PubMed ID: 37841017
[TBL] [Abstract][Full Text] [Related]
4. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Lebwohl M; Warren RB; Sofen H; Imafuku S; Paul C; Szepietowski JC; Spelman L; Passeron T; Vritzali E; Napoli A; Kisa RM; Buck A; Banerjee S; Thaçi D; Blauvelt A
Br J Dermatol; 2024 Apr; 190(5):668-679. PubMed ID: 38226713
[TBL] [Abstract][Full Text] [Related]
5. Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis.
Xu Y; Li Z; Wu S; Guo L; Jiang X
Front Immunol; 2023; 14():1180170. PubMed ID: 37334353
[TBL] [Abstract][Full Text] [Related]
6. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
7. Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
Armstrong AW; Park SH; Patel V; Hogan M; Wang WJ; Davidson D; Chirikov V
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2589-2603. PubMed ID: 37525000
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M
J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942
[TBL] [Abstract][Full Text] [Related]
9. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B; Thaçi D; Sofen H; Kircik L; Gordon KB; Foley P; Rich P; Paul C; Bagel J; Colston E; Throup J; Kundu S; Sekaran C; Linaberry M; Banerjee S; Papp KA
J Am Acad Dermatol; 2023 Jan; 88(1):40-51. PubMed ID: 36115523
[TBL] [Abstract][Full Text] [Related]
10. Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
Galluzzo M; Vellucci L; Marcelli L; Paganini C; Bianchi L; Talamonti M
Expert Opin Pharmacother; 2023 Jun; 24(9):981-988. PubMed ID: 37147879
[TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis.
Jin JQ; Spencer RK; Reddy V; Bhutani T; Liao W
Ther Clin Risk Manag; 2023; 19():413-423. PubMed ID: 37223005
[TBL] [Abstract][Full Text] [Related]
12. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
Gooderham MJ; Hong HC; Litvinov IV
Skin Therapy Lett; 2022 Nov; 27(6):1-5. PubMed ID: 36469536
[TBL] [Abstract][Full Text] [Related]
13. Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far.
Martins A; Lé AM; Torres T
Drugs Context; 2023; 12():. PubMed ID: 37168876
[TBL] [Abstract][Full Text] [Related]
14. Deucravacitinib in the treatment of psoriasis.
Estevinho T; Lé AM; Torres T
J Dermatolog Treat; 2023 Dec; 34(1):2154122. PubMed ID: 36453809
[TBL] [Abstract][Full Text] [Related]
15. Deucravacitinib in moderate-to-severe psoriasis.
Vu A; Maloney V; Gordon KB
Immunotherapy; 2022 Nov; 14(16):1279-1290. PubMed ID: 36373503
[TBL] [Abstract][Full Text] [Related]
16. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D; Strober B; Gordon KB; Foley P; Gooderham M; Morita A; Papp KA; Puig L; Menter MA; Colombo MJ; Elbez Y; Kisa RM; Ye J; Napoli AA; Wei L; Banerjee S; Merola JF; Gottlieb AB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):495-510. PubMed ID: 35025062
[TBL] [Abstract][Full Text] [Related]
17. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW; Gooderham M; Warren RB; Papp KA; Strober B; Thaçi D; Morita A; Szepietowski JC; Imafuku S; Colston E; Throup J; Kundu S; Schoenfeld S; Linaberry M; Banerjee S; Blauvelt A
J Am Acad Dermatol; 2023 Jan; 88(1):29-39. PubMed ID: 35820547
[TBL] [Abstract][Full Text] [Related]
18. The preclinical discovery and development of deucravacitinib for the treatment of psoriasis.
Coscarella G; Malvaso D; Mannino M; Caldarola G; Fossati B; De Simone C; Chiricozzi A; Peris K
Expert Opin Drug Discov; 2023; 18(11):1201-1208. PubMed ID: 37574849
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan.
Hagino T; Saeki H; Fujimoto E; Kanda N
J Dermatolog Treat; 2024 Dec; 35(1):2307489. PubMed ID: 38305215
[TBL] [Abstract][Full Text] [Related]
20. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
Catlett IM; Hu Y; Gao L; Banerjee S; Gordon K; Krueger JG
J Allergy Clin Immunol; 2022 Jun; 149(6):2010-2020.e8. PubMed ID: 34767869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]